ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies

By The Science Advisory Board staff writers

June 29, 2020 -- ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further testing and possible inclusion in the company's PolyTope monoclonal antibody therapy against COVID-19.

The selected lead antibodies are the result of functional screening of over 300 antibodies analyzed from human and llama cells utilizing proprietary phage display technology. These antibodies support the company's goal of generating a multitarget therapy that retains efficacy, even as SARS-CoV-2 continues to evolve.

The company is preparing to test the lead antibodies against additional mutated strains of the virus with preclinical studies slotted to begin this summer.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here